Evidence map›Paper›PMID 42491087›Full record

ArticleAmerican journal of translational research2026

Reserpine-induced hypotension through catecholamine and RAAS/nitric oxide/endothelin dysregulation.

Ya Mo, Ming Jiang, Hong-Lei Zhou, Jia-Wen Wang, Rui Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ya MoShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology Shanghai 200237, P. R. China.
Ming JiangShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology Shanghai 200237, P. R. China.
Hong-Lei ZhouShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology Shanghai 200237, P. R. China.
Jia-Wen WangShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology Shanghai 200237, P. R. China.
Rui WangShanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology Shanghai 200237, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aims to investigate the mechanisms underlying reserpine-induced hypotension.

methodsA rat model of hypotension was established by reserpine administration, followed by levodopa (L-DOPA) intervention. Arterial blood pressure, histopathologic changes in the heart and kidneys, the levels of norepinephrine (NE), the renin-angiotensin-aldosterone system (RAAS), and endothelial function markers were systematically evaluated.

resultsReserpine significantly lowered blood pressure and caused myofibrillar disarray, tubular epithelial degeneration, and elevated biomarkers of cardiac and renal injury. These pathologic changes were attributable primarily to depletion of NE and dysregulation of vasoactive regulatory systems. L-DOPA treatment restored NE and vasoactive mediator levels and markedly ameliorated hypotension and cardiorenal injury.

conclusionReserpine induces hypotension and cardiorenal injury through suppression of the catecholamine system, accompanied by dysregulation of the RAAS and nitric oxide/endothelin (NO/ET) system, whereas L-DOPA attenuates these pathologic changes.

Indexed as

cardio-renal injuryHypotensionNO/ET systemnorepinephrineRAASreserpine

Identifiers

PMID42491087
PMCPMC13376037

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.